Literature DB >> 8383944

Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension.

M C Nahata1, K I Koranyi, S D Gadgil, D M Hilligoss, H G Fouda, M J Gardner.   

Abstract

Azithromycin is an azalide antibiotic. On the basis of data in adults, azithromycin appears to have a greater distribution into tissues, a longer elimination half-life, and a lower incidence of adverse effects than the macrolide antibiotic erythromycin. However, little about the pharmacokinetics of azithromycin in children is known. The objective of our study was to characterize the pharmacokinetics of azithromycin after oral administration of multiple doses of suspension to children with streptococcal pharyngitis. Fourteen children (6 to 15 years of age) received a single oral dose of 10 mg of azithromycin per kg of body weight on day 1 followed by single daily doses of 5 mg/kg on days 2 to 5. Each child fasted overnight before receiving the final dose on day 5. Blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h after this last dose. Concentrations of azithromycin in serum were measured by a specific high-performance liquid chromatography-mass spectrometry method. The mean +/- standard deviation for maximum concentration of drug in serum, time to maximum concentration of drug in serum, and area under the curve (0 to 24 h) were 383 +/- 142 ng/ml, 2.4 +/- 1.1 h, and 3,109 +/- 1,033 ng.h/ml, respectively. Concentrations in serum at 0 h (predose) and at 24, 48, and 72 h after the final dose were 67 +/- 31, 64 +/- 24, 41 +/- 17, and 29 +/- 14 ng/ml, respectively. Thus, once-daily administration of azithromycin resulted in sustained systemic exposure to the drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383944      PMCID: PMC187659          DOI: 10.1128/AAC.37.2.314

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers.

Authors:  P Coates; R Daniel; A C Houston; J H Antrobus; T Taylor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues.

Authors:  R M Shepard; G S Duthu; R A Ferraina; M A Mullins
Journal:  J Chromatogr       Date:  1991-04-19

4.  Comparative in vitro potencies of nine new macrolides.

Authors:  P B Fernandes; D J Hardy
Journal:  Drugs Exp Clin Res       Date:  1988

5.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

Review 6.  The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.

Authors:  N Bahal; M C Nahata
Journal:  Ann Pharmacother       Date:  1992-01       Impact factor: 3.154

Review 7.  Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications.

Authors:  R H Drew; H A Gallis
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

Review 8.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

  8 in total
  11 in total

1.  Interplay between pediatric pharmacy practice and research to influence patient care.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  Ensuring safe and effective medication use in pediatric patients.

Authors:  Milap C Nahata
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

3.  Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team.

Authors:  L Y Ngo; R Yogev; W M Dankner; W T Hughes; S Burchett; J Xu; B Sadler; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 4.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

5.  Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections.

Authors:  J J Roord; B H Wolf; M M Gossens; J L Kimpen
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children.

Authors:  P Marchisio; N Principi; E Sala; L Lanzoni; S Sorella; A Massimini
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 7.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  Pharmacokinetics of azithromycin in pediatric patients with acute otitis media.

Authors:  M C Nahata; K I Koranyi; D R Luke; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

9.  Treatment of adenotonsillar hypertrophy: A prospective randomized trial comparing azithromycin vs. fluticasone.

Authors:  Seyed Mostafa Hashemi Jazi; Behrouz Barati; Azadeh Kheradmand
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

10.  Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis.

Authors:  Stacey L Martiniano; Brandie D Wagner; Laney Brennan; Michael F Wempe; Peter L Anderson; Charles L Daley; Meg Anthony; Jerry A Nick; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2021-05-21       Impact factor: 5.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.